Title |
Epigallocatechin gallate inhibits sphere formation of neuroblastoma BE(2)-C cells
|
---|---|
Published in |
Environmental Health and Preventive Medicine, September 2011
|
DOI | 10.1007/s12199-011-0239-5 |
Pubmed ID | |
Authors |
Noriyuki Nishimura, Tri Budi Hartomo, Thi Van Huyen Pham, Myeong Jin Lee, Tomoto Yamamoto, Satoru Morikawa, Daiichiro Hasegawa, Hiroki Takeda, Keiichiro Kawasaki, Yoshiyuki Kosaka, Nobuyuki Yamamoto, Ikuko Kubokawa, Takeshi Mori, Tomoko Yanai, Akira Hayakawa, Yasuhiro Takeshima, Kazumoto Iijima, Masafumi Matsuo, Hisahide Nishio |
Abstract |
A growing number of epidemiological studies have demonstrated that the consumption of green tea inhibits the growth of a variety of cancers. Epigallocatechin gallate (EGCG), the most abundant catechin in green tea, has been shown to have an anti-cancer effect against many cancers. Most cancers are believed to be initiated from and maintained by a small population of tumor-initiating cells (TICs) that are responsible for chemotherapeutic resistance and tumor relapse. In neuroblastoma, an aggressive pediatric tumor that often relapses and has a poor prognosis, TICs were recently identified as spheres grown in a serum-free non-adherent culture used for neural crest stem cell growth. Although EGCG has been reported to induce growth arrest and apoptosis in neuroblastoma cells, its effect on neuroblastoma TICs remains to be defined. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 36 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 8 | 22% |
Student > Bachelor | 5 | 14% |
Student > Master | 4 | 11% |
Researcher | 4 | 11% |
Other | 3 | 8% |
Other | 3 | 8% |
Unknown | 9 | 25% |
Readers by discipline | Count | As % |
---|---|---|
Biochemistry, Genetics and Molecular Biology | 8 | 22% |
Agricultural and Biological Sciences | 6 | 17% |
Medicine and Dentistry | 6 | 17% |
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 6% |
Unspecified | 1 | 3% |
Other | 4 | 11% |
Unknown | 9 | 25% |